BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Riverain Medical Announces International Availability of Its OnGuard Computer-Aided Detection Technology and SoftView Enhanced Chest Imaging Technology


11/19/2008 7:40:47 AM

DAYTON, Ohio, Nov. 18 /PRNewswire/ -- Riverain Medical, an industry leader and innovator in computer-aided detection (CAD) and diagnostic technologies, today announced that two of the company's products, the OnGuard(TM) Chest X-ray CAD system and the SoftView(TM) Enhanced Chest Imaging technology, have been awarded CE marks and Canadian device licenses. Both products are commercially available to clinicians in the European Union and Canada.

Riverain's OnGuard Chest X-ray CAD works in conjunction with the reading of standard digital chest X-rays to quickly and comprehensively identify solitary pulmonary nodules that may be early-stage lung cancer. In Europe and Canada, lung cancer is the leading cause of death due to cancer. Lung cancer accounts for 20 percent of all cancer deaths in Europe and 27 percent in Canada.(1) When detected in its earliest stages, the survival rate for lung cancer patients more than triples. Unfortunately, few lung cancers are detected at this early stage.(2)

"Throughout the world, lung cancer continues to kill people at an alarming rate as patients often go undiagnosed with the disease until it has progressed to an advanced stage," said Diane Hirakawa, Chairman and CEO of Riverain Medical. "Riverain is excited to provide the clinical community and patients in Europe and Canada with the OnGuard technology, allowing radiologists across the globe to better detect lung cancer at an earlier stage."

Riverain's SoftView technology creates an enhanced soft tissue image of the chest by suppressing bone on a standard chest X-ray. SoftView increases image clarity to help radiologists better detect and diagnose medical conditions such as pulmonary nodules, pneumothoraces and improperly placed lines and tubes.

"With the availability of SoftView in Europe and Canada, radiologists can now feel more confident that their interpretation is as accurate as possible," said Hirakawa.

About Riverain Medical

Riverain Medical, LLC is a privately-held medical software technology company headquartered in Dayton, Ohio, specializing in technologies that enhance radiologists' detection and diagnostic skills. Riverain's mission is to save lives by improving the detection and diagnosis of diseases and other clinical conditions.

(1) International Union Against Cancer's New European Cancer Figures, 2007 and Public Health Agency of Canada's Canadian Cancer Statistics, 2008.

CONTACT: Jane Hauser of Schwartz Communications, +1-781-684-0770,
RiverainMedical@schwartz-pr.com; or Amanda Pressel of Riverain Medical,
+1-937-531-5084, APressel@riverainmedical.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->